日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

一项针对晚期实体瘤患者（包括广泛期小细胞肺癌患者）的AT-101联合顺铂和依托泊苷的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-013-9999-7
Schelman, William R; Mohammed, Tabraiz A; Traynor, Anne M; Kolesar, Jill M; Marnocha, Rebecca M; Eickhoff, Jens; Keppen, Michael; Alberti, Dona B; Wilding, George; Takebe, Naoko; Liu, Glenn
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

一项针对晚期实体瘤患者的间歇给药伏立诺他联合硼替佐米的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-013-0035-8
Deming, Dustin A; Ninan, Jacob; Bailey, Howard H; Kolesar, Jill M; Eickhoff, Jens; Reid, Joel M; Ames, Matthew M; McGovern, Renee M; Alberti, Dona; Marnocha, Rebecca; Espinoza-Delgado, Igor; Wright, John; Wilding, George; Schelman, William R
发表日期：2014
文献求助 收藏

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

一项针对晚期恶性肿瘤患者的伏立诺他联合硼替佐米治疗的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-013-0029-6
Schelman, William R; Traynor, Anne M; Holen, Kyle D; Kolesar, Jill M; Attia, Steven; Hoang, Tien; Eickhoff, Jens; Jiang, Zhisheng; Alberti, Dona; Marnocha, Rebecca; Reid, Joel M; Ames, Matthew M; McGovern, Renee M; Espinoza-Delgado, Igor; Wright, John J; Wilding, George; Bailey, Howard H
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Vorinostat 与硼替佐米联合用于晚期恶性肿瘤患者，可直接改变靶基因的转录

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-013-2242-6
Kolesar Jill M, Traynor Anne M, Holen Kyle D, Hoang Tien, Seo Songwon, Kim Kyungmann, Alberti Dona, Espinoza-Delgado Igor, Wright John J, Wilding George, Bailey Howard H, Schelman William R
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

莫特沙芬钆和多柔比星治疗晚期恶性肿瘤的I期临床试验

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-009-9364-z
Traynor, Anne M; Thomas, James P; Ramanathan, Ramesh K; Mody, Tarak D; Alberti, Dona; Wilding, George; Bailey, Howard H
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

癌症患者体内3-氨基吡啶-2-甲醛硫代氨基脲（Triapine®）的群体药代动力学

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-010-1331-z
Kolesar, Jill; Brundage, Richard C; Pomplun, Marcia; Alberti, Dona; Holen, Kyle; Traynor, Anne; Ivy, Percy; Wilding, George
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

MN-029 在晚期实体瘤患者中的剂量递增、安全性和耐受性研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-009-9264-2
Traynor, Anne M; Gordon, Michael S; Alberti, Dona; Mendelson, David S; Munsey, Mark S; Wilding, George; Gammans, Richard E; Read, William L
发表日期：2010
文献求助 收藏

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

3-氨基吡啶-2-甲醛硫代氨基脲（3-AP）联合伊立替康治疗难治性实体瘤患者的最大耐受剂量和生物学效应

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-010-1250-z
Choi, Brian S; Alberti, Dona B; Schelman, William R; Kolesar, Jill M; Thomas, James P; Marnocha, Rebecca; Eickhoff, Jens C; Ivy, S Percy; Wilding, George; Holen, Kyle D
发表日期：2010
文献求助 收藏

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

在符合条件的患者中，年龄和合并症并不能预测 I 期化疗的剂量限制性毒性。

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-009-1084-8
LoConte, Noelle K; Smith, Maureen; Alberti, Dona; Bozeman, Jeffrey; Cleary, James F; Setala, Ashley N; Wodtke, Geoff; Wilding, George; Holen, Kyle D
毒理研究
发表日期：2010
文献求助 收藏

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

编码前列腺酸性磷酸酶的DNA疫苗在D0期前列腺癌患者中的安全性和免疫学疗效

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2008.19.9968
McNeel, Douglas G; Dunphy, Edward J; Davies, James G; Frye, Thomas P; Johnson, Laura E; Staab, Mary Jane; Horvath, Dorothea L; Straus, Jane; Alberti, Dona; Marnocha, Rebecca; Liu, Glenn; Eickhoff, Jens C; Wilding, George
肿瘤
前列腺癌
肿瘤免疫
免疫/内分泌
发表日期：2009
文献求助 收藏